The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process
Abstract
Advanced glycation end product (AGE) formation that occurs with aging and diabetes leads to the cross-linking of proteins and subsequent changes in the physicochemical properties of tissues. Cellular responses to AGE that lead to either pathological conditions or removal of AGE are mediated by a number of receptors that have been identified on various cell types such as macrophages, endothelial cells, and smooth-muscle cells. Mechanisms by which AGE affect the cardiovascular system include AGE cross-linking of long-lived proteins such as collagen and elastin and altered cellular responses. Alagebrium (3-phenacyl-4,5-dimethylthiazolium chloride, ALT-711) is the first drug in a new class of thiazolium therapeutic agents that break established AGE cross-links between proteins. In animal studies, alagebrium was effective in reducing large artery stiffness, slowing pulse-wave velocity, enhancing cardiac output, and improving left ventricular diastolic distensibility. In human studies to determine safety and efficacy, alagebrium was safe and well tolerated. In the first phase 2 clinical study, alagebrium improved arterial compliance in elderly patients with vascular stiffening. In two subsequent phase 2 clinical studies, one addressing diastolic heart failure and the other addressing systolic hypertension, alagebrium was effective in improving cardiac function and uncontrolled systolic blood pressure, particularly in more severely affected patients. Additional clinical studies to determine the utility of alagebrium in treating cardiovascular disorders associated with aging are in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franklin, S. S., Larson, M. G., Khan, S. A., Wong, N. D., Leip, E. P., Kannel, W. B., & Levy, D. (2001) · Circulation · doi:10.1161/01.cir.103.9.1245 · Cited by 1,390
Role of galectin-3 in diabetic nephropathy
Iacobini, C., Amadio, L., Oddi, G., Ricci, C., Barsotti, P., Missori, S., Sorcini, M., Di Mario, U., Pricci, F., & Pugliese, G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077402.95720.b4 · Cited by 99
Cited by
Townsend, R. R., Wilkinson, I. B., Schiffrin, E. L., Avolio, A. P., Chirinos, J. A., Cockcroft, J. R., Heffernan, K. S., Lakatta, E. G., McEniery, C. M., Mitchell, G. F., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000033 · Cited by 1,473
Cavalcante, J. L., Lima, J. A. C., Redheuil, A., & Al-Mallah, M. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.017 · Cited by 841
Arterial Aging: Is It an Immutable Cardiovascular Risk Factor?
Najjar, S. S., Scuteri, A., & Lakatta, E. G. (2005) · Hypertension · doi:10.1161/01.hyp.0000177474.06749.98 · Cited by 640
Ageing of the conduit arteries
Greenwald, S. (2007) · The Journal of Pathology · doi:10.1002/path.2101 · Cited by 637
Advanced glycation end products: Key players in skin aging?
Gkogkolou, P., & Böhm, M. (2012) · Dermato-Endocrinology · doi:10.4161/derm.22028 · Cited by 584
Age-related vascular stiffening: causes and consequences
Kohn, J. C., Lampi, M. C., & Reinhart-King, C. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00112 · Cited by 440
“Amino groups on proteins react with aldehydes or ketones on the reducing sugars to form shift bases that rearrange to Amadori products and are further modified to produce AGEs (Bakris et al., 2004; Sell and Monnier, 2012).”
BackgroundInfluentialAdvanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212217 · Cited by 381
The Hypertension Paradox — More Uncontrolled Disease despite Improved Therapy
Chobanian, A. V. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0903829 · Cited by 372
Oxidative stress in early diabetic nephropathy: fueling the fire
Singh, D. K., Winocour, P., & Farrington, K. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.212 · Cited by 353
Oxidative Stress in Health and Disease
Reddy, V. P. (2023) · Biomedicines · doi:10.3390/biomedicines11112925 · Cited by 333
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
Advanced Glycation End-Products (AGEs) and Heart Failure: Pathophysiology and Clinical Implications
Hartog, J. W. L., Voors, A. A., Bakker, S. J. L., Smit, A. J., & van Veldhuisen, D. J. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.09.009 · Cited by 299
Urinary Proteomics in Diabetes and CKD
Rossing, K., Mischak, H., Dakna, M., Zürbig, P., Novak, J., Julian, B. A., Good, D. M., Coon, J. J., Tarnow, L., & Rossing, P. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091025 · Cited by 283
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
Reddy, V. P., & Beyaz, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.016 · Cited by 266
Safar, M. E., Blacher, J., & Jankowski, P. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.039 · Cited by 141
Audard, J., Godet, T., Blondonnet, R., Joffredo, J.-B., Paquette, B., Belville, C., Lavergne, M., Gross, C., Pasteur, J., Bouvier, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45798-5 · Cited by 35
Comprehensive Nanorobotic Control of Human Morbidity and Aging
Freitas, R. A. (2010) · The Future of Aging · doi:10.1007/978-90-481-3999-6_23 · Cited by 16
Sanon, V., Patel, S., Sanon, S., Rodriguez, R., Pham, S., & Chilton, R. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s97619 · Cited by 6
“At the cellular level, microvascular disease and vascular stiffness are mediated by the interaction of receptors such as lectin-like oxidized low-density lipoprotein receptor-1 and macrophage scavenger receptors to advanced glycation end products.(32,33)”
Background
Metadata
- Authors
- BAKRIS, G., BANK, A., KASS, D., NEUTEL, J., PRESTON, R., & OPARIL, S.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12
- Volume
- 17
- Issue
- 12
- Pages
- S23-S30
- ISSN
- 0895-7061 (ISSN-L)
- OpenAlex
- W1967959058
- Cited by
- 210
- References
- 2
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.